Epinephrine bitartrate is under clinical development by De Motu Cordis and currently in Phase I for Anaphylaxis. According to GlobalData, Phase I drugs for Anaphylaxis have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Epinephrine bitartrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Epinephrine bitartrate overview
Epinephrine bitartrate (DMC-IH1) is under development for the treatment of anaphylaxis. The drug candidate is administered through inhalational route in the form of dry powder. It acts by targeting alpha and beta-adrenergic receptors.
De Motu Cordis overview
De Motu Cordis is a medical device company developing drug device combination products for advanced drug delivery. De Motu Cordis is headquartered in Australia.
For a complete picture of Epinephrine bitartrate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
